reference/28146516

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/28146516

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Research Support, N.I.H., Extramural\|Research Support, Non-U.S. Gov't
endingPage	795
issn	0344-5704 1432-0843
issueIdentifier	6
pageRange	789-795
publicationName	Cancer Chemotherapy and Pharmacology
startingPage	789
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_669f303425b390c444e89c37dcfed3c6
bibliographicCitation	Schaar D, Goodell L, Aisner J, Cui XX, Han ZT, Chang R, Martin J, Grospe S, Dudek L, Riley J, Manago J, Lin Y, Rubin EH, Conney A, Strair RK. A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies. Cancer Chemother Pharmacol. 2006 Jun;57(6):789–95. doi: 10.1007/s00280-005-0125-1. PMID: 16231182.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_db27eac1baf78941d5833a3aec4e639c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5325445c4469591f73f07af182401b18 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1195b76e4e11d04a0e95adfee44366ee http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bc99cbcf100b3517972d9eacd0ac7307 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a7a72dd172f8a65580850065a96935a8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f2b34158341710bf0b0271a14b1d0324 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6c29eb0aa6534975ac9b8dfbfa7effb4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d57d6b66f91670eaa2f0bfe9b8f329f4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_63e4d41013ca5b11a197bbc2f928bef4 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1fa33729fbda101f7a0b3d563341dd36 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ef0f887fc07c28357879de56101d24fd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a59a2eb99cd9bcc95fd8ed2a2fc134c8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_94efa45878427f05d42d00810cabc35d http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c91ce5db41ea2f1ce5fe32239fcf94a1 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cefe360d4f24df0ae1fa8e07e711e78e
date	2005-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/16231182 https://doi.org/10.1007/s00280-005-0125-1
isPartOf	https://portal.issn.org/resource/ISSN/0344-5704 https://portal.issn.org/resource/ISSN/1432-0843 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2664
language	English
source	https://www.crossref.org/ https://scigraph.springernature.com/ https://pubmed.ncbi.nlm.nih.gov/
title	A phase I clinical trial of 12- O-tetradecanoylphorbol-13-acetate for patients with relapsed/refractory malignancies
discusses	http://id.nlm.nih.gov/mesh/M0021224 http://id.nlm.nih.gov/mesh/M0001483
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8756 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7521 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9350 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_5792807d3e9e12df929850eb909e1bdf http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7620 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8135 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID27924 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10698 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7732 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9826034 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7952

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129922365 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128915368

Total number of triples: 55.